Paclitaxel, Pembrolizumab & Olaparib in Previously Treated Advanced

Updated 05/14/2024

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the safety and clinical activity of paclitaxel plus olaparib and pembrolizumab in patients with previously treated advanced Gastric Cancer (GC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04209686
Study type	Interventional
Source	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact	Colleen Apostol, RN
Phone	410-614-3644
Email	GIClinicalTrials@jhmi.edu
Status	Recruiting
Phase	Phase 2
Start date	July 31, 2020
Completion date	April 2028

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04977193` - A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma	Early Phase 1
	Recruiting	`NCT04993378` - Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy
	Recruiting	`NCT05583383` - A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab	N/A
	Completed	`NCT06238752` - First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC	Phase 2
	Recruiting	`NCT02240524` - Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer	Phase 3
	Completed	`NCT02447380` - Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment	Phase 2
	Not yet recruiting	`NCT06203600` - Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, The PARAMMUNE Trial	Phase 2/Phase 3
	Recruiting	`NCT05677490` - mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma	Phase 3
	Completed	`NCT02448329` - Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	Phase 2
	Completed	`NCT02615730` - PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma	Phase 1/Phase 2
	Recruiting	`NCT05041153` - Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma	Early Phase 1
	Terminated	`NCT02449655` - Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy	Phase 2
	Completed	`NCT02449551` - Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment	Phase 2
	Not yet recruiting	`NCT04174339` - PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer	N/A
	Completed	`NCT02599324` - Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors	Phase 1/Phase 2
	Recruiting	`NCT06028737` - Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer	Phase 2/Phase 3
	Recruiting	`NCT04675866` - Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer	N/A
	Completed	`NCT02447406` - Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment	Phase 1/Phase 2
	Recruiting	`NCT03159819` - Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma	N/A